An exploratory open-label multicentre phase I/II trial evaluating the safety and efficacy of postnatal or prenatal and postnatal administration of allogeneic expanded fetal mesenchymal stem cells for the treatment of severe osteogenesis imperfecta in infants and fetuses: the BOOSTB4 trial protocol

Rachael Sagar(University College Hospital), Cecilia Götherström(Karolinska Institutet), Mikael Sundin(Karolinska University Hospital), Lilian Walther–Jallow(Karolinska Institutet), E. J. T. Verweij(Leiden University Medical Center), Ralph J. B. Sakkers(University Medical Center Utrecht), Peter Lindgren(Karolinska University Hospital), Dick Oepkes(Leiden University Medical Center), Mirko Rehberg(University Hospital Cologne), Lyn S. Chitty(Great Ormond Street Hospital), Caroline A. Lindemans(University Medical Center Utrecht), Wouter H. Nijhuis(University Medical Center Utrecht), Anna L. David(University College Dublin), Melissa Hill(Great Ormond Street Hospital), Annabelle Forsmark, Magnus Westgren, Göran Hermerén(Lund University), Nils‐Eric Sahlin(Lund University), Oliver Semler(University Hospital Cologne), Mats Johansson(Lund University), Vera Franzen, Eva Åström(Karolinska University Hospital), Catherine DeVile(Great Ormond Street Hospital for Children NHS Foundation Trust), Belinda Crowe(Great Ormond Street Hospital for Children NHS Foundation Trust)
BMJ Open
June 1, 2024
Cited by 20


Related Papers